ICML 2023 | Efficacy and safety of glofitamab for patients with Richter’s transformation
Richter’s transformation (RT) is characterized by the development of an aggressive lymphoma, usually diffuse large B-cell lymphoma (DLCBL), in a patient with underlying chronic lymphocytic leukemia (CLL). This patient population has very poor outcomes and represents an area of high unmet medical need. Carmelo Carlo-Stella, MD, PhD, Humanitas Clinical and Research Center, Rozzano, Italy, discusses the inclusion of patients with RT in the NP30179 trial (NCT03075696), investigating glofitamab as a single agent therapy for relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). Prof. Carlo-Stella shares the promising efficacy and safety data from this patient cohort, in which four out of the five patients who achieved a complete remission (CR) remained in CR at data cutoff. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant or advisory role ADC Therapeutics, Celgene/Bristol Myers Squibb, Karyopharm, Novartis, Sanofi, Roche, Merck Sharp & Dohme, Scenic Biotech
Honoraria: Merck Sharp & Dohme, Janssen Oncology, AstraZeneca, Celgene, Incyte, Gilead Sciences, Roche
